<DOC>
	<DOCNO>NCT02849873</DOCNO>
	<brief_summary>The Absorption Systematic Pharmacokinetics IDP-123 Lotion Comparison Tazorac Cream .</brief_summary>
	<brief_title>Absorption Systematic Pharmacokinetics IDP-123 Lotion Comparison With Tazorac Cream</brief_title>
	<detailed_description>Randomized study evaluate absorption systematic pharmacokinetics IDP-123 lotion comparison Tazorac Cream subject moderate severe acne vulgaris maximal use condition .</detailed_description>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Key Male female , least 9 year age ( least 12 year age Tazorac Cream ) . Verbal write informed consent must obtain . Subjects less age consent must sign assent study parent legal guardian must sign informed consent ( subject reach age consent study reconsented next study visit ) . Subject must score 3 ( moderate ) 4 ( severe ) Evaluator 's Global Severity assessment screen baseline visit . Subjects facial acne inflammatory lesion count less 20 40 . Subjects facial acne noninflammatory lesion count less 20 100 . Key Use investigational drug device within 30 day enrollment participation research study concurrent study . Any dermatological condition face could interfere clinical evaluation acne conglobate , acne fulminans , secondary acne , perioral dermatitis , clinically significant rosacea , gramnegative folliculitis , dermatitis , eczema . Any underlying disease dermatological condition face require use interfere topical systemic therapy make evaluation lesion count inconclusive . Subjects facial beard mustache could interfere study assessment . Subjects 2 facial nodule .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>